Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation

Kidney International

Volumn 58, Issue 4, 2000, Pages 1788-1796

  Westeel, François Pierre ^a,b,c   Mazouz, Hakim ^a,b,c   Ezaitouni, Fatima ^a,b,c   Hottelart, Carine ^a,b,c   Ivan, Christina ^a,b,c   Fardellone, Patrice ^a,b,c   Brazier, Michel ^a,b,c   El Esper, Isabelle ^a,b,c   Petit, Jacques ^a,b,c   Achard, Jean Michel ^a,b,c   Pruna, André ^a,b,c   Fournier, Albert ^a,b,c  

^a Department of Nephrology and Internal Medicine ^*  (France)

^b Laboratory of Hormonology   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Bone remodeling; Cyclosporine; Kidney transplant; Osteopenia; Prednisone

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; OSTEOCALCIN; PARATHYROID HORMONE; PREDNISONE; STEROID; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; BONE REMODELING; COMPUTER ASSISTED TOMOGRAPHY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; ORGAN TRANSPLANTATION; OSTEOPENIA; PRIORITY JOURNAL; STEROID THERAPY;

EID: 0033797498     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00341.x     Document Type: Article

References (44)

1. New developments in the pathogenesis and treatment of steroid induced osteoporos
2. Glucocorticoid induced osteoporosis: Both in vivo and in vitro concentration of glucocorticoids higher than physiological levels attenuate osteoblast differentiation
3. Vertebral osteoporosis in rheumatoid arthritis patients: Effect of low dose prednisone therapy
4. Rapid suppression of plasma alkaline phosphatase activity after renal transplantation in patients with osteodystrophy
5. Post-transplantation bone disease: The role of immuno-suppressive agents and the skeleton
6. The fate of bone after transplantation
7. Cyclosporin A induces in vivo inhibition of resorption and stimulation of formation in rat
8. Cyclosporin does not affect the absolute rate of cortical bone at the organ level in the growing rat
9. Cyclosporin in cadaveric renal transplantation 5 year follow-up of a multicentre trial
10. Alkaline phosphatase levels in renal transplant recipients receiving cyclosporin
11. Cyclosporin A-induced transient rise in plasma alkaline phosphatase in kidney transplant patients
12. Sequential changes of biochemical bone parameters after kidney transplantation
13. Rapid loss of vertebral mineral density after renal transplantation
14. Bone histology in renal transplant patients receiving cyclosporin
15. Changes in bone mass early after kidney transplantation
16. Long-term bone loss in kidney transplant recipients: A cross-sectional and longitudinal study
17. Bone mineral density after kidney transplantation: A cross sectional study in 190 graft recipients up to 20 years after transplantation
18. Long-term bone loss after renal transplantation: Comparison of immunosuppressive regimens
19. Disorders of bone and mineral metabolism after transplantation
20. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation
21. Osteoporosis after cardiac transplantation
22. Factors involved in the loss of bone mineral density after renal transplantation
23. Long term bone densitometry post renal transplantation in patients treated with either cyclosporin or prednisolone
24. Bone loss in long term transplantation: Histopathology and densitometry analysis
25. Effects of three immunosuppressive regimens on vertebral bone density in renal transplantation recipients
26. Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 vitamin D levels two years after kidney transplantation
27. Clinical observation of metabolic change occurring in renal transplant recipient receiving ketoconazole
28. Which bone density measurement?
29. Urinary excretion of pyridinoline cross links correlates with bone turn over measured on lilac crest biopsy in patients with vertebral osteoperosis
30. High performance liquid chromatography of 3 hydroxypyridinium derivates as new markers of bone resorption
31. Circulating intact PTH measured by a two site immunochemiluminometric assay
32. The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase
33. Six osteocalcin assays compared
34. A competitive protein binding assay for 25 OH cholecalciferol and 25 OH cryocalciferol in serum
35. Quality control of DXA instrument
36. Vertebral mineral determination by quantitative computed tomography QCT: Accuracy of single and dual energy measurements
37. Mineralized bone loss at different sites in dialysis patients: Implications for prevention
38. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone (1-34). A randomized trial
39. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis
40. Combined treatment with cyclosporin A and cortisone acetate minimized the adverse bone effects of either agent alone
41. Mechanism of bone loss after liver transplantation: A histomorphometric analysis
42. Mechanism of bone loss following allogenic and autologous hemopoietic stem cell transplantation
43. Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis